Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | President, R&D | March 06, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date March 06, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,473 |
Reported balance
After 2023-03-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-06 · Purchase · Acquired 3,000 · Balance 11,473 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. F2: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended. |
| Common StockSEC Table I · non-derivative | Direct | 13,473 |
Reported balance
After 2023-03-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-07 · Purchase · Acquired 2,000 · Balance 13,473 F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 14,473 |
Reported balance
After 2023-03-10 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-03-10 · Purchase · Acquired 1,000 · Balance 14,473 F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 20,771 |
Reported balance
After 2023-03-10 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-03-10 · Exercise / conversion · Acquired 6,298 · Balance 20,771 F5: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). |
| Common StockSEC Table I · non-derivative | Direct | 18,339 |
Reported balance
After 2023-03-10 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2023-03-10 · Tax withholding · Disposed 2,432 · Balance 18,339 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,596 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Exercise / conversion · Disposed 6,298 · Balance 12,596 F6: Each RSU represents a contingent right to receive one share of the Company common stock. F7: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F2: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended.
F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F5: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
F6: Each RSU represents a contingent right to receive one share of the Company common stock.
F7: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2023 Filed Mar 14, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 6,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018545 · doc4.xml · derivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,596 Underlying: Common Stock · 6,298 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company common stock. F7 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. F7 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,432 | $6.52 | $15,856.64 |
DisclosureSEC source: 0001209191-23-018545 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,339 Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 6,298 | $6.52 | $41,062.96 |
DisclosureSEC source: 0001209191-23-018545 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | PurchaseCommon Stock | 1,000 | $6.50 | $6,500.00 |
DisclosureSEC source: 0001209191-23-018545 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,473 F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 07, 2023 Filed Mar 14, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | PurchaseCommon Stock | 2,000 | $7.04 | $14,088.00 |
DisclosureSEC source: 0001209191-23-018545 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,473 F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 06, 2023 Filed Mar 14, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | PurchaseCommon Stock | 3,000 | $7.48 | $22,453.50 |
DisclosureSEC source: 0001209191-23-018545 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,473 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. F2 · balance_after: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 22:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061704 · doc4.xml · derivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 Underlying: Common Stock · 3,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F6 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. F6 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 22:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,033 | $17.23 | $17,798.59 |
DisclosureSEC source: 0001209191-22-061704 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,009 F4 · kind: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs. F5 · balance_after: The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 22:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-061704 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were received by the Reporting Person in connection with vesting of restricted stock units ("RSUs"). F2 · price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · balance_after: Includes 278 shares acquired on January 31, 2022 and 1 share acquired on July 31, 2022, each under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 23:45 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 18,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-018657 · doc4.xml · derivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,894 Underlying: Common Stock · 18,894 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 23:45 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 28,341 | $0.00 Strike: $77.77 | $0.00 |
DisclosureSEC source: 0001209191-22-018657 · doc4.xml · derivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,341 Underlying: Common Stock · 28,341 shares Expires 2032-03-10 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the March 10, 2022 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 662 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · derivative · entry 18 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,944 Underlying: Common Stock · 662 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,024 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · derivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,024 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 27 | $180.62 | $4,876.77 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,663 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.47 to $180.81, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 206 | $179.58 | $36,993.09 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,690 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.31 to $179.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 103 | $178.99 | $18,436.25 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,896 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.29 to $179.26, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 223 | $176.83 | $39,432.04 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,999 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.42 to $177.36, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 67 | $175.89 | $11,784.84 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.31 to $176.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 137 | $174.65 | $23,927.31 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,289 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.03 to $175.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 91 | $173.29 | $15,769.63 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,426 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.97 to $173.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 248 | $172.38 | $42,749.52 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,517 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.97 to $172.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 254 | $171.47 | $43,553.20 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.94 to $171.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 213 | $170.46 | $36,308.98 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,019 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.78 to $170.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 117 | $168.82 | $19,752.14 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,232 F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.61 to $169.27, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 662 | $46.00 | $30,452.00 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,024 | $27.60 | $28,262.40 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · derivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 Underlying: Common Stock · 3,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F14 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. F14 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,498 | $168.43 | $252,308.14 |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,663 Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-070012 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,250 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · derivative · entry 25 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 8,250 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F22 · derivative.exercise_date: On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100 | $182.96 | $18,296.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 24 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 853 | $182.30 | $155,498.06 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 23 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,161 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F21 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.79 to $182.74, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 500 | $180.29 | $90,147.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 22 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,014 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F20 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.92 to $180.86, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 500 | $179.36 | $89,680.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 21 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,514 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F19 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.89 to $179.58, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 500 | $178.21 | $89,104.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 20 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,014 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.80 to $178.37, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 800 | $176.20 | $140,956.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 19 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,514 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.84 to $176.75, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 900 | $175.13 | $157,618.98 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 18 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,314 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.71 to $175.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 200 | $173.14 | $34,627.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,214 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.64 to $173.63, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 200 | $171.30 | $34,260.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,414 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.04 to $171.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 400 | $168.77 | $67,508.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,614 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.40 to $169.07, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $167.06 | $50,118.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,014 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.59 to $167.39, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $165.80 | $49,739.01 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,314 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.40 to $166.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $164.77 | $49,430.01 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,614 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.37 to $165.13, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 200 | $162.83 | $32,565.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,914 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.42 to $163.23, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $161.63 | $48,489.99 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,114 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.29 to $162.21, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $160.52 | $48,156.99 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,414 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.24 to $160.94, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $158.42 | $47,526.99 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,714 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.25 to $158.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 200 | $157.02 | $31,404.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,014 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.71 to $157.33, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $156.24 | $46,872.99 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,214 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.69 to $156.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100 | $154.38 | $15,438.00 |
DisclosureSEC source: 0001209191-21-068836 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,514 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.